Short-term treatment of primary fibromyalgia with the 5-HT3-receptor antagonist tropisetron. Results of a randomized, double-blind, placebo-controlled multicenter trial in 418 patients

International Journal of Clinical Pharmacology Research

Volumn 21, Issue 1, 2001, Pages 1-13

  Farber L ^a   Stratz, T H ^a   Bruckle W ^a   Spath M ^a   Pongratz, D ^a   Lautenschlager J ^a   Kotter I ^a   Zoller B ^a   Peter, H H ^a   Neeck, G ^a   Welzel, D ^a   Muller W ^a  

^a Hochrheininst Rehabilitationforsh ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FIBROMYALGIA; GASTROINTESTINAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PAIN ASSESSMENT; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SYMPTOM;

ADOLESCENT; ADULT; AGED; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HALF-LIFE; HUMANS; INDOLES; MALE; MIDDLE AGED; PAIN MEASUREMENT; PROSPECTIVE STUDIES; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT3; SEROTONIN ANTAGONISTS;

EID: 0034775909     PISSN: 02511649     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (65)

1. Tender points, depressive and functional symptoms: Comparison between fibromyalgia and major depression
2. A clinical overview of the fibromyalgia syndrome
3. Clinical features in patients with chronic muscle pain - with special reference to fibromyalgia
4. Sleep in fibromyalgia patients: Subjective and objective findings
5. Criteria for the classification of fibromyalgia. Report of the multicenter criteria committee
6. A randomized controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia
7. Short term effects of ibuprofen in primary fibromyalgia syndrome: A double-blind, placebo-controlled trial
8. A blinded, placebo-controlled evaluation of Tramadol in the management of fibromyalgia pain
9. Efficacy of Ultram® (Tramadol HCl) treatment of fibromyalgia syndrome (FMS): Secondary outcomes report
10. A double blind crossover trial of prednisone versus placebo in the treatment of fibrositis
11. Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study
12. Double-blind study of dethiopin versus placebo in the treatment of primary fibromyalgia syndrome
13. A randomized placebo-controlled trial of substained-release amitriptyline in primary fibromyalgia
14. Comparison of amitriptyline, cyclobenzaprine and placebo in the treatment of fibromyalgia
15. A double-blind placebo controlled trial of fluoxetine in fibromyalgia
16. A randomized double-blind crossover trial of flurexine and amitriptyline in the treatment of fibromyalgia
17. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia
18. Moclobemide in fibromyalgia: A double-blind, randomized study vs placebo and amitriptyline
19. Moclobemid in fibromyalgia syndrome: A double-blind placebo-controlled study
20. Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazaolam: A double-blind, placebo-controlled study
21. Fibromyalgia patients opinion on drugs II. Benzodiazepine and muscle relaxants
22. Are there subgroups of fibromyalgia?
23. Pain, disability and physical functioning in subgroups of patients with fibromyalgia
24. Serum amino acids in fibrositis/fibromyalgia syndrome
25. Biochemical Abnormalities in fibromyalgia syndrome
26. Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study
27. 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome
28. Effects of subtance P on nociceptive and non-noceceptive trigeminal brain stem neurons
29. Intrathecal morphine inhibits substance P release from mammalian spinal cord in vivo
30. Elevated CSF levels of substance P and high incidence of Raynaud phenomenon in patients with fibromyalgia: New features for diagnosis
31. Elevated cerebrospinal fluid levels of substance P in patients with the fibromyalgia syndrome
32. 5-Hydroxytryptamine-facilitated release of substance P from rat spinal cord slices is mediated by nitric oxide and cyclic GMP
33. 3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy
34. 3 receptor antagonists: Differences and similarities
35. 3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting
36. 3 receptor antagonists
37. 3-receptor antagonist GR38032F on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain
38. 3-receptors in the central nervous system
39. 3-receptor antagonists
40. 3-receptors in fibromyalgia - a new therapy concept?
41. 3 antagonist, in healthy human subjects
42. Tropisetron. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential as an antiemetic
43. Clinical pharmacokinetics of ondansetron. A review
44. Die generalisierte Tendomyopathie (GTM) Teil I: Klinik, Verlauf und Differentialdiagnose
45. The measurement of clinical pain intensity: A comparison of six methods
46. Development of preliminary criteria for response to treatment in fibromyalgia syndrome
47. Selection of measures suitable for evaluating change in fibromyalgia clinical trials
48. Sleep electroencephalography (EEG) and the clinical response to amitriptyline in patients with fibromyalgia
49. The effects of cyclobenzaprine on sleep physiology and symptoms in patients with fibromyalgia
50. 3-receptor antagonists inhibit sensory neuropaptide release from the rat spinal cord
51. Dorsal column stimulation induces release of serotonin and substance P in the cat dorsal horn
52. Antinociception induced by microinjection of substance P into the A7 catecholamine cell group in the rat
53. Dual actions of substance P on nociception: Possible role of endogenous opioids
54. 3 receptors
55. Sub-anesthetic doses of bupivacaine or lidocaine increase peripheral ICS-205 930-induced analgesia against inflammatory pain in rats
56. 3 receptor antagonist with anxiolytic-like properties
57. 3 receptor antagonists in development as anxiolytics
58. 3 receptor antagonists and migraine therapy
59. 3) receptor antagonist in the prevention of migraine attacks. A complex answer to a simple question
60. 3 receptor antagonism modulates a noxious visceral pseudoaffective reflex
61. The effects of granisetron, ICS 205-930 and ondansetron on the visceral pain reflex induces by duodenal distension
62. Noradrenergic mediation of spinal antinoception by 5HT: Characterization of receptor subtypes
63. 3 receptor subtypes interacting with special noradrenergic systems in two tests for nociception
64. Noradrenergic and perinergic involvement in special antinociception by 5-hydroxytryptamine and 2-methyl-5-hydroxytryptamine
65. 3 receptors